BACKGROUND AND OBJECTIVE: With the introduction of the ViroSeq™ HIV-1 Genotyping System (ViroSeq™ assay) into China, it is important to evaluate the impact of the diversity of HIV-1 genotypes found in China on the performance of the ViroSeq™ assay compared with an in-house method. MATERIALS AND METHODS: A total of 318 plasma samples, collected from 206 HIV-1-infected patients receiving antiretroviral therapy and 112 treatment-naïve HIV-1-infected patients, were used for evaluating the concordance of genotypes, genotypic resistance mutations, and phenotypic resistance between the ViroSeq™ assay and an in-house method for analyzing HIV-1 drug resistance in China. RESULTS: A concordance of genotypes between the ViroSeq™ assay and the in-house method was observed for the 313 samples (98.4%), using the Stanford University HIV Drug Resistance Database (Version 6.0.5). The overall concordances of drug-resistance-related mutations (DRRMs) in the HIV-1 protease (PR) and reverse transcriptase (RT) coding sequences within the HIV-1 pol gene, scored by the ViroSeq™ assay and the in-house method, were 99.5% and 98.1%, respectively. Discrepancies between the two methods were found in 38 samples assayed for protease inhibitor (PI) DRRMs, 36 samples assayed for nucleoside reverse transcriptase inhibitor (NRTI) DRRMs, and 72 samples assayed for non-nucleoside reverse transcriptase inhibitor (NNRTI) DRRMs, and 100%, 88.9%, and 87.5% of the samples with discrepancies for PI, NRTI, and NNRTI DRRMs, respectively, were genotyped as subtype B. One NNRTI mutation (the RT mutation Y318F) was reported only by the ViroSeq™ assay, and this discrepancy resulted from the difference in the pol gene lengths generated by the two systems. Furthermore, the overall concordance of phenotypic resistance was 94.7% (301/318) between the two methods. CONCLUSION: The ViroSeq™ assay will be a useful tool for monitoring clinical drug resistance and for better management of HIV-1 patients receiving antiretroviral therapy in China.
BACKGROUND AND OBJECTIVE: With the introduction of the ViroSeq™ HIV-1 Genotyping System (ViroSeq™ assay) into China, it is important to evaluate the impact of the diversity of HIV-1 genotypes found in China on the performance of the ViroSeq™ assay compared with an in-house method. MATERIALS AND METHODS: A total of 318 plasma samples, collected from 206 HIV-1-infectedpatients receiving antiretroviral therapy and 112 treatment-naïve HIV-1-infectedpatients, were used for evaluating the concordance of genotypes, genotypic resistance mutations, and phenotypic resistance between the ViroSeq™ assay and an in-house method for analyzing HIV-1 drug resistance in China. RESULTS: A concordance of genotypes between the ViroSeq™ assay and the in-house method was observed for the 313 samples (98.4%), using the Stanford University HIV Drug Resistance Database (Version 6.0.5). The overall concordances of drug-resistance-related mutations (DRRMs) in the HIV-1 protease (PR) and reverse transcriptase (RT) coding sequences within the HIV-1 pol gene, scored by the ViroSeq™ assay and the in-house method, were 99.5% and 98.1%, respectively. Discrepancies between the two methods were found in 38 samples assayed for protease inhibitor (PI) DRRMs, 36 samples assayed for nucleoside reverse transcriptase inhibitor (NRTI) DRRMs, and 72 samples assayed for non-nucleoside reverse transcriptase inhibitor (NNRTI) DRRMs, and 100%, 88.9%, and 87.5% of the samples with discrepancies for PI, NRTI, and NNRTI DRRMs, respectively, were genotyped as subtype B. One NNRTI mutation (the RT mutation Y318F) was reported only by the ViroSeq™ assay, and this discrepancy resulted from the difference in the pol gene lengths generated by the two systems. Furthermore, the overall concordance of phenotypic resistance was 94.7% (301/318) between the two methods. CONCLUSION: The ViroSeq™ assay will be a useful tool for monitoring clinical drug resistance and for better management of HIV-1patients receiving antiretroviral therapy in China.
Authors: Jing Yun Li; Han Ping Li; Lin Li; Hong Li; Zhe Wang; Kun Yang; Zuo Yi Bao; Dao Min Zhuang; Si Yang Liu; Yong Jian Liu; Hui Xing; Yi Ming Shao Journal: Cell Res Date: 2005 Nov-Dec Impact factor: 25.617
Authors: Jessica D Church; Dana Jones; Tamara Flys; Donald Hoover; Natalia Marlowe; Shu Chen; Chanjuan Shi; James R Eshleman; Laura A Guay; J Brooks Jackson; Newton Kumwenda; Taha E Taha; Susan H Eshleman Journal: J Mol Diagn Date: 2006-09 Impact factor: 5.568
Authors: M Mracna; G Becker-Pergola; J Dileanis; L A Guay; S Cunningham; J B Jackson; S H Eshleman Journal: J Clin Microbiol Date: 2001-12 Impact factor: 5.948
Authors: J D Baxter; D L Mayers; D N Wentworth; J D Neaton; M L Hoover; M A Winters; S B Mannheimer; M A Thompson; D I Abrams; B J Brizz; J P Ioannidis; T C Merigan Journal: AIDS Date: 2000-06-16 Impact factor: 4.177
Authors: Diana D Huang; Susan H Eshleman; Donald J Brambilla; Paul E Palumbo; James W Bremer Journal: J Clin Microbiol Date: 2003-07 Impact factor: 5.948